JNJ vs XOM: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
Exxon Mobil Corporation · Energy
$154.46
-40.5% upside to fair value
Grade C
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
XOM trades at a lower forward P/E
(23.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
XOM |
| Current Price |
$230.69 |
$154.46 |
| Fair Value Estimate |
$255.61 |
$91.87 |
| Upside to Fair Value |
+10.8%
|
-40.5%
|
| Market Cap |
$555.9B |
$642.0B |
| Forward P/E |
26.8x
|
23.2x
|
| EV / EBITDA |
18.5x
|
10.3x
|
| Price / Sales |
5.8x
|
2.0x
|
| Price / FCF |
28.2x
|
27.2x
|
| Revenue Growth YoY |
+9.9%
|
-1.3%
|
| Gross Margin |
69.1%
|
21.7%
|
| Operating Margin |
26.9%
|
10.5%
|
| Return on Equity |
26.5%
|
11.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.54%
|
3.68%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Exxon Mobil Corporation operates as a global integrated oil and gas company with significant operations in upstream, energy products, chemical products, and specialty products segments. The company benefits from a highly experienced management team with decades of internal tenure, led by CEO Darren Woods. Despite strong cash flow generation and operational scale, Exxon is currently overvalued, tr…
Accumulation Zones
| Metric |
JNJ |
XOM |
| Zone Low |
$191.71 |
$68.90 |
| Zone High |
$217.27 |
$78.09 |
| In Buy Zone? |
No
|
No
|